A phase II, monotherapy study of YM155, a novel survivin suppressant, in previously treated advanced stage non-small cell lung cancer (NSCLC)

被引：0

作者：

Giaccone, Giuseppe ^{[1
]}

Zatloukal, Petr ^{[2
]}

Roubec, Jaromir ^{[3
]}

Musil, Jaromir ^{[4
]}

Kuta, Milan ^{[5
]}

van Klaveren, R. J. ^{[6
]}

Chaudhary, Subhash ^{[7
]}

Gunther, Adrie ^{[8
]}

Shamsili, Setareh ^{[8
]}

Kazei, Dmitri ^{[8
]}

Verbeeck, Frank ^{[8
]}

机构：

[1] Natl Canc Inst, Bethesda, MD USA

[2] FN Bulovka, Prague, Czech Republic

[3] FN Ostrava Poruba, Ostrava, Czech Republic

[4] FN Motole, Prague, Czech Republic

[5] Nemocnice Chomutuv, Chomutov, Czech Republic

[6] Erasmus MC, Rotterdam, Netherlands

[7] Onkol Cent JG Mendla, Novy Jicin, Czech Republic

[8] Astellas Pharma Europe BV, Leiderdorp, Netherlands

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3597S / 3597S

页数：1